I63 I61 I60 S06.5 S06.4 S06 D33 D43 C71 G01 G00 G02 G03 G04 G05 G93.1
Conditions
Interventions
Group 1: Treatment group: Patients of treatment group receive the experimental treatment for cognitive rehabilitation in virtual reality over at least 18 treatment sessions, lasting 30 minutes each.
G
Sponsors
Living Brain GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • legally competent male and female patients aged 18 years and older, • who are in inpatient neurological rehabilitation treatment due to acute damage to or disease of the brain (e.g. cerebral infarction, intracerebral hemorrhage, subarachnoid hemorrhage, subdural or epidural intracranial hemorrhage, traumatic brain injury, brain tumor, meningitis or encephalitis, hypoxic encephalitis), • and have agreed to participate in the study. • Full functionality for one arm • Sufficient vision (or corrected) in the central field of vision, no double vision • No previous psychiatric illness in the patient's medical history
Exclusion criteria
Exclusion criteria: • Psychiatric comorbidities: Acute: depression, schizophrenia, suicidality, dementia • Dementia and the MMST score below 24 points • Known overreaction to visual stimulation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - change of cognitive performance (measured by TL-D, AKT, TMT A&B, FEPVR, LPS3, WMS-R), - change of morbidity concerning acute neurological diseases in rehabilitation in contrast to trial start (EQ-5D VAS) | — |
Secondary
| Measure | Time frame |
|---|---|
| - change of affect (PANAS), - self-reported Quality of Life (SF36), - change of performance in a realistic setting, relevant for AdL, in contrast to status at trial start (FEPVR) | — |
Countries
Germany
Contacts
Public ContactKarsten Krakow
Asklepios Neurologische Klinik Falkenstein
Outcome results
None listed